Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives
Identifieur interne : 000701 ( PascalFrancis/Corpus ); précédent : 000700; suivant : 000702Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives
Auteurs : Naoyuki Masuda ; Osamu Yamamoto ; Masahiro Fujii ; Tetsuro Ohgami ; Jiro Fujiyasu ; Toru Kontani ; Ayako Moritomo ; Masaya Orita ; Hiroyuki Kurihara ; Hironobu Koga ; Shunji Kageyama ; Mitsuaki Ohta ; Hiroshi Inoue ; Toshifumi Hatta ; Masafumi Shintani ; Hiroshi Suzuki ; Kenji Sudo ; Yasuaki Shimizu ; Eiichi Kodama ; Masao Matsuoka ; Masatoshi Fujiwara ; Tomoyuki Yokota ; Shiro Shigeta ; Masanori BabaSource :
- Bioorganic & medicinal chemistry [ 0968-0896 ] ; 2005.
Descripteurs français
- Pascal (Inist)
- Relation structure activité, Synthèse chimique, Sulfonamide, Thiazole dérivé, Nitrile, Benzène dérivé, Hétérocycle soufre azote, Composé non nucléoside, Inhibiteur enzyme, Inhibiteur reverse transcriptase, RNA-directed DNA polymerase, Antiviral, Virus HIV1, In vitro, Anti hiv, Benzènesulfonamide(5-chloro-2-cyano-N-[3,4-diméthyl-5-isopropylthiazolin-2-ylidène]), Benzènesulfonamide(5-bromo-N-[4-chloro-5-isopropyl-3-méthylthiazolin-2-ylidène]-2-hydroxy), Benzène-1,4-dicarbonitrile dérivé, Benzènesulfonamide(2,5-dicyano-N-[3,4-diméthyl-5-isopropylthiazolin-2-ylidène]), YM 215389, YM 228855.
English descriptors
- KwdEn :
Abstract
In a previous study, we described the structure-activity relationships (SARs) for a series of thiazolidenebenzenesulfonamide derivatives. These compounds were found to be highly potent inhibitors of the wild type (WT) and Y181C mutant reverse transcriptases (RTs) and modest inhibitors of K103N RT. These molecules are thus considered to be a novel class of non-nucleoside HIV-1 RT inhibitors (NNRTIs). In this paper, we have examined the effects of substituents on both the thiazolidene and benzenesulfonamide moieties. Introduction of a 2-cyanophenyl ring into these moieties significantly enhanced anti-HIV-1 activity, whereas a 2-hydroxyphenyl group endowed potent activity against RTs, including K103N and Y181C mutants. Among the series of molecules examined, 101 and 18b (YM-228855), combinations of 2-cyanophenyl and 4-methyl-5-isopropylthiazole moieties, showed extremely potent anti-HIV-1 activity. The EC50 values of 101 and 18b were 0.0017 and 0.0018 μM, respectively. These values were lower than that of efavirenz (3). Compound 11g (YM-215389), a combination of 2-hydroxyphenyl and 4-chloro-5-isopropylthiazole moieties, proved to be the most active against both K103N and Y181C RTs with IC50 values of 0.043 and 0.013 μM, respectively.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 05-0202368 INIST |
|---|---|
| ET : | Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives |
| AU : | MASUDA (Naoyuki); YAMAMOTO (Osamu); FUJII (Masahiro); OHGAMI (Tetsuro); FUJIYASU (Jiro); KONTANI (Toru); MORITOMO (Ayako); ORITA (Masaya); KURIHARA (Hiroyuki); KOGA (Hironobu); KAGEYAMA (Shunji); OHTA (Mitsuaki); INOUE (Hiroshi); HATTA (Toshifumi); SHINTANI (Masafumi); SUZUKI (Hiroshi); SUDO (Kenji); SHIMIZU (Yasuaki); KODAMA (Eiichi); MATSUOKA (Masao); FUJIWARA (Masatoshi); YOKOTA (Tomoyuki); SHIGETA (Shiro); BABA (Masanori) |
| AF : | Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka/Tsukuba, Ibaraki 305-8585/Japon (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut., 9 aut., 10 aut., 11 aut., 12 aut., 13 aut., 14 aut., 15 aut., 16 aut., 17 aut., 18 aut.); Laboratory of Virus Immunology, Institute for Virus Research, Kyoto University, 53 Syogoin, Kawaramachi/Sakyo-ku, Kyoto 606-8507/Japon (19 aut., 20 aut.); Rational Drug Design Laboratories, 4-1-1, Misato/Matsukawa-Machi, Fukushima 960-1242/Japon (21 aut., 22 aut.); Department of Microbiology, School of Medicine, Fukushima Medical University/I Hikarigaoka, Fukushima 960-1295/Japon (23 aut.); Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University/8-35-1 Sakuragaoka, Kagoshima 890-8544/Japon (24 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Bioorganic & medicinal chemistry; ISSN 0968-0896; Royaume-Uni; Da. 2005; Vol. 13; No. 4; Pp. 949-961; Bibl. 15 ref. |
| LA : | Anglais |
| EA : | In a previous study, we described the structure-activity relationships (SARs) for a series of thiazolidenebenzenesulfonamide derivatives. These compounds were found to be highly potent inhibitors of the wild type (WT) and Y181C mutant reverse transcriptases (RTs) and modest inhibitors of K103N RT. These molecules are thus considered to be a novel class of non-nucleoside HIV-1 RT inhibitors (NNRTIs). In this paper, we have examined the effects of substituents on both the thiazolidene and benzenesulfonamide moieties. Introduction of a 2-cyanophenyl ring into these moieties significantly enhanced anti-HIV-1 activity, whereas a 2-hydroxyphenyl group endowed potent activity against RTs, including K103N and Y181C mutants. Among the series of molecules examined, 101 and 18b (YM-228855), combinations of 2-cyanophenyl and 4-methyl-5-isopropylthiazole moieties, showed extremely potent anti-HIV-1 activity. The EC50 values of 101 and 18b were 0.0017 and 0.0018 μM, respectively. These values were lower than that of efavirenz (3). Compound 11g (YM-215389), a combination of 2-hydroxyphenyl and 4-chloro-5-isopropylthiazole moieties, proved to be the most active against both K103N and Y181C RTs with IC50 values of 0.043 and 0.013 μM, respectively. |
| CC : | 002B02S05 |
| FD : | Relation structure activité; Synthèse chimique; Sulfonamide; Thiazole dérivé; Nitrile; Benzène dérivé; Hétérocycle soufre azote; Composé non nucléoside; Inhibiteur enzyme; Inhibiteur reverse transcriptase; RNA-directed DNA polymerase; Antiviral; Virus HIV1; In vitro; Anti hiv; Benzènesulfonamide(5-chloro-2-cyano-N- [3,4-diméthyl-5-isopropylthiazolin-2-ylidène]); Benzènesulfonamide(5-bromo-N-[4-chloro-5-isopropyl-3-méthylthiazolin-2-ylidène]-2-hydroxy); Benzène-1,4-dicarbonitrile dérivé; Benzènesulfonamide(2,5-dicyano-N-[3,4-diméthyl-5-iso propylthiazolin-2-ylidène]); YM 215389; YM 228855 |
| FG : | Chlore Composé organique; Brome Composé organique; Nucleotidyltransferases; Transferases; Enzyme; Virus immunodéficience humaine; Lentivirus; Retroviridae; Virus |
| ED : | Structure activity relation; Chemical synthesis; Sulfonamide; Thiazole derivatives; Nitrile; Benzene derivatives; Sulfur nitrogen heterocycle; Non nucleoside compound; Enzyme inhibitor; Reverse transcriptase inhibitor; RNA-directed DNA polymerase; Antiviral; HIV-1 virus; In vitro |
| EG : | Chlorine Organic compounds; Bromine Organic compounds; Nucleotidyltransferases; Transferases; Enzyme; Human immunodeficiency virus; Lentivirus; Retroviridae; Virus |
| SD : | Relación estructura actividad; Síntesis química; Sulfonamida; Tiazol derivado; Nitrilo; Benceno derivado; Heterociclo azufre nitrógeno; Compuesto no nucleósido; Inhibidor enzima; Inhibitor reverse transcriptase; RNA-directed DNA polymerase; Antiviral; HIV-1 virus; In vitro |
| LO : | INIST-26564.354000125945790020 |
| ID : | 05-0202368 |
Links to Exploration step
Pascal:05-0202368Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives</title><author><name sortKey="Masuda, Naoyuki" sort="Masuda, Naoyuki" uniqKey="Masuda N" first="Naoyuki" last="Masuda">Naoyuki Masuda</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Yamamoto, Osamu" sort="Yamamoto, Osamu" uniqKey="Yamamoto O" first="Osamu" last="Yamamoto">Osamu Yamamoto</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Fujii, Masahiro" sort="Fujii, Masahiro" uniqKey="Fujii M" first="Masahiro" last="Fujii">Masahiro Fujii</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ohgami, Tetsuro" sort="Ohgami, Tetsuro" uniqKey="Ohgami T" first="Tetsuro" last="Ohgami">Tetsuro Ohgami</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Fujiyasu, Jiro" sort="Fujiyasu, Jiro" uniqKey="Fujiyasu J" first="Jiro" last="Fujiyasu">Jiro Fujiyasu</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kontani, Toru" sort="Kontani, Toru" uniqKey="Kontani T" first="Toru" last="Kontani">Toru Kontani</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Moritomo, Ayako" sort="Moritomo, Ayako" uniqKey="Moritomo A" first="Ayako" last="Moritomo">Ayako Moritomo</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Orita, Masaya" sort="Orita, Masaya" uniqKey="Orita M" first="Masaya" last="Orita">Masaya Orita</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kurihara, Hiroyuki" sort="Kurihara, Hiroyuki" uniqKey="Kurihara H" first="Hiroyuki" last="Kurihara">Hiroyuki Kurihara</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Koga, Hironobu" sort="Koga, Hironobu" uniqKey="Koga H" first="Hironobu" last="Koga">Hironobu Koga</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kageyama, Shunji" sort="Kageyama, Shunji" uniqKey="Kageyama S" first="Shunji" last="Kageyama">Shunji Kageyama</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ohta, Mitsuaki" sort="Ohta, Mitsuaki" uniqKey="Ohta M" first="Mitsuaki" last="Ohta">Mitsuaki Ohta</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Inoue, Hiroshi" sort="Inoue, Hiroshi" uniqKey="Inoue H" first="Hiroshi" last="Inoue">Hiroshi Inoue</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hatta, Toshifumi" sort="Hatta, Toshifumi" uniqKey="Hatta T" first="Toshifumi" last="Hatta">Toshifumi Hatta</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Shintani, Masafumi" sort="Shintani, Masafumi" uniqKey="Shintani M" first="Masafumi" last="Shintani">Masafumi Shintani</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Suzuki, Hiroshi" sort="Suzuki, Hiroshi" uniqKey="Suzuki H" first="Hiroshi" last="Suzuki">Hiroshi Suzuki</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sudo, Kenji" sort="Sudo, Kenji" uniqKey="Sudo K" first="Kenji" last="Sudo">Kenji Sudo</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Shimizu, Yasuaki" sort="Shimizu, Yasuaki" uniqKey="Shimizu Y" first="Yasuaki" last="Shimizu">Yasuaki Shimizu</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kodama, Eiichi" sort="Kodama, Eiichi" uniqKey="Kodama E" first="Eiichi" last="Kodama">Eiichi Kodama</name><affiliation><inist:fA14 i1="02"><s1>Laboratory of Virus Immunology, Institute for Virus Research, Kyoto University, 53 Syogoin, Kawaramachi</s1><s2>Sakyo-ku, Kyoto 606-8507</s2><s3>JPN</s3><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Matsuoka, Masao" sort="Matsuoka, Masao" uniqKey="Matsuoka M" first="Masao" last="Matsuoka">Masao Matsuoka</name><affiliation><inist:fA14 i1="02"><s1>Laboratory of Virus Immunology, Institute for Virus Research, Kyoto University, 53 Syogoin, Kawaramachi</s1><s2>Sakyo-ku, Kyoto 606-8507</s2><s3>JPN</s3><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Fujiwara, Masatoshi" sort="Fujiwara, Masatoshi" uniqKey="Fujiwara M" first="Masatoshi" last="Fujiwara">Masatoshi Fujiwara</name><affiliation><inist:fA14 i1="03"><s1>Rational Drug Design Laboratories, 4-1-1, Misato</s1><s2>Matsukawa-Machi, Fukushima 960-1242</s2><s3>JPN</s3><sZ>21 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Yokota, Tomoyuki" sort="Yokota, Tomoyuki" uniqKey="Yokota T" first="Tomoyuki" last="Yokota">Tomoyuki Yokota</name><affiliation><inist:fA14 i1="03"><s1>Rational Drug Design Laboratories, 4-1-1, Misato</s1><s2>Matsukawa-Machi, Fukushima 960-1242</s2><s3>JPN</s3><sZ>21 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Shigeta, Shiro" sort="Shigeta, Shiro" uniqKey="Shigeta S" first="Shiro" last="Shigeta">Shiro Shigeta</name><affiliation><inist:fA14 i1="04"><s1>Department of Microbiology, School of Medicine, Fukushima Medical University</s1><s2>I Hikarigaoka, Fukushima 960-1295</s2><s3>JPN</s3><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Baba, Masanori" sort="Baba, Masanori" uniqKey="Baba M" first="Masanori" last="Baba">Masanori Baba</name><affiliation><inist:fA14 i1="05"><s1>Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University</s1><s2>8-35-1 Sakuragaoka, Kagoshima 890-8544</s2><s3>JPN</s3><sZ>24 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0202368</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 05-0202368 INIST</idno><idno type="RBID">Pascal:05-0202368</idno><idno type="wicri:Area/PascalFrancis/Corpus">000701</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives</title><author><name sortKey="Masuda, Naoyuki" sort="Masuda, Naoyuki" uniqKey="Masuda N" first="Naoyuki" last="Masuda">Naoyuki Masuda</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Yamamoto, Osamu" sort="Yamamoto, Osamu" uniqKey="Yamamoto O" first="Osamu" last="Yamamoto">Osamu Yamamoto</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Fujii, Masahiro" sort="Fujii, Masahiro" uniqKey="Fujii M" first="Masahiro" last="Fujii">Masahiro Fujii</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ohgami, Tetsuro" sort="Ohgami, Tetsuro" uniqKey="Ohgami T" first="Tetsuro" last="Ohgami">Tetsuro Ohgami</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Fujiyasu, Jiro" sort="Fujiyasu, Jiro" uniqKey="Fujiyasu J" first="Jiro" last="Fujiyasu">Jiro Fujiyasu</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kontani, Toru" sort="Kontani, Toru" uniqKey="Kontani T" first="Toru" last="Kontani">Toru Kontani</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Moritomo, Ayako" sort="Moritomo, Ayako" uniqKey="Moritomo A" first="Ayako" last="Moritomo">Ayako Moritomo</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Orita, Masaya" sort="Orita, Masaya" uniqKey="Orita M" first="Masaya" last="Orita">Masaya Orita</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kurihara, Hiroyuki" sort="Kurihara, Hiroyuki" uniqKey="Kurihara H" first="Hiroyuki" last="Kurihara">Hiroyuki Kurihara</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Koga, Hironobu" sort="Koga, Hironobu" uniqKey="Koga H" first="Hironobu" last="Koga">Hironobu Koga</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kageyama, Shunji" sort="Kageyama, Shunji" uniqKey="Kageyama S" first="Shunji" last="Kageyama">Shunji Kageyama</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ohta, Mitsuaki" sort="Ohta, Mitsuaki" uniqKey="Ohta M" first="Mitsuaki" last="Ohta">Mitsuaki Ohta</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Inoue, Hiroshi" sort="Inoue, Hiroshi" uniqKey="Inoue H" first="Hiroshi" last="Inoue">Hiroshi Inoue</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hatta, Toshifumi" sort="Hatta, Toshifumi" uniqKey="Hatta T" first="Toshifumi" last="Hatta">Toshifumi Hatta</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Shintani, Masafumi" sort="Shintani, Masafumi" uniqKey="Shintani M" first="Masafumi" last="Shintani">Masafumi Shintani</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Suzuki, Hiroshi" sort="Suzuki, Hiroshi" uniqKey="Suzuki H" first="Hiroshi" last="Suzuki">Hiroshi Suzuki</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sudo, Kenji" sort="Sudo, Kenji" uniqKey="Sudo K" first="Kenji" last="Sudo">Kenji Sudo</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Shimizu, Yasuaki" sort="Shimizu, Yasuaki" uniqKey="Shimizu Y" first="Yasuaki" last="Shimizu">Yasuaki Shimizu</name><affiliation><inist:fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kodama, Eiichi" sort="Kodama, Eiichi" uniqKey="Kodama E" first="Eiichi" last="Kodama">Eiichi Kodama</name><affiliation><inist:fA14 i1="02"><s1>Laboratory of Virus Immunology, Institute for Virus Research, Kyoto University, 53 Syogoin, Kawaramachi</s1><s2>Sakyo-ku, Kyoto 606-8507</s2><s3>JPN</s3><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Matsuoka, Masao" sort="Matsuoka, Masao" uniqKey="Matsuoka M" first="Masao" last="Matsuoka">Masao Matsuoka</name><affiliation><inist:fA14 i1="02"><s1>Laboratory of Virus Immunology, Institute for Virus Research, Kyoto University, 53 Syogoin, Kawaramachi</s1><s2>Sakyo-ku, Kyoto 606-8507</s2><s3>JPN</s3><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Fujiwara, Masatoshi" sort="Fujiwara, Masatoshi" uniqKey="Fujiwara M" first="Masatoshi" last="Fujiwara">Masatoshi Fujiwara</name><affiliation><inist:fA14 i1="03"><s1>Rational Drug Design Laboratories, 4-1-1, Misato</s1><s2>Matsukawa-Machi, Fukushima 960-1242</s2><s3>JPN</s3><sZ>21 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Yokota, Tomoyuki" sort="Yokota, Tomoyuki" uniqKey="Yokota T" first="Tomoyuki" last="Yokota">Tomoyuki Yokota</name><affiliation><inist:fA14 i1="03"><s1>Rational Drug Design Laboratories, 4-1-1, Misato</s1><s2>Matsukawa-Machi, Fukushima 960-1242</s2><s3>JPN</s3><sZ>21 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Shigeta, Shiro" sort="Shigeta, Shiro" uniqKey="Shigeta S" first="Shiro" last="Shigeta">Shiro Shigeta</name><affiliation><inist:fA14 i1="04"><s1>Department of Microbiology, School of Medicine, Fukushima Medical University</s1><s2>I Hikarigaoka, Fukushima 960-1295</s2><s3>JPN</s3><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Baba, Masanori" sort="Baba, Masanori" uniqKey="Baba M" first="Masanori" last="Baba">Masanori Baba</name><affiliation><inist:fA14 i1="05"><s1>Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University</s1><s2>8-35-1 Sakuragaoka, Kagoshima 890-8544</s2><s3>JPN</s3><sZ>24 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Bioorganic & medicinal chemistry</title><title level="j" type="abbreviated">Bioorg. med. chem.</title><idno type="ISSN">0968-0896</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Bioorganic & medicinal chemistry</title><title level="j" type="abbreviated">Bioorg. med. chem.</title><idno type="ISSN">0968-0896</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term><term>Benzene derivatives</term><term>Chemical synthesis</term><term>Enzyme inhibitor</term><term>HIV-1 virus</term><term>In vitro</term><term>Nitrile</term><term>Non nucleoside compound</term><term>RNA-directed DNA polymerase</term><term>Reverse transcriptase inhibitor</term><term>Structure activity relation</term><term>Sulfonamide</term><term>Sulfur nitrogen heterocycle</term><term>Thiazole derivatives</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Relation structure activité</term><term>Synthèse chimique</term><term>Sulfonamide</term><term>Thiazole dérivé</term><term>Nitrile</term><term>Benzène dérivé</term><term>Hétérocycle soufre azote</term><term>Composé non nucléoside</term><term>Inhibiteur enzyme</term><term>Inhibiteur reverse transcriptase</term><term>RNA-directed DNA polymerase</term><term>Antiviral</term><term>Virus HIV1</term><term>In vitro</term><term>Anti hiv</term><term>Benzènesulfonamide(5-chloro-2-cyano-N-[3,4-diméthyl-5-isopropylthiazolin-2-ylidène])</term><term>Benzènesulfonamide(5-bromo-N-[4-chloro-5-isopropyl-3-méthylthiazolin-2-ylidène]-2-hydroxy)</term><term>Benzène-1,4-dicarbonitrile dérivé</term><term>Benzènesulfonamide(2,5-dicyano-N-[3,4-diméthyl-5-isopropylthiazolin-2-ylidène])</term><term>YM 215389</term><term>YM 228855</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In a previous study, we described the structure-activity relationships (SARs) for a series of thiazolidenebenzenesulfonamide derivatives. These compounds were found to be highly potent inhibitors of the wild type (WT) and Y181C mutant reverse transcriptases (RTs) and modest inhibitors of K103N RT. These molecules are thus considered to be a novel class of non-nucleoside HIV-1 RT inhibitors (NNRTIs). In this paper, we have examined the effects of substituents on both the thiazolidene and benzenesulfonamide moieties. Introduction of a 2-cyanophenyl ring into these moieties significantly enhanced anti-HIV-1 activity, whereas a 2-hydroxyphenyl group endowed potent activity against RTs, including K103N and Y181C mutants. Among the series of molecules examined, 101 and 18b (YM-228855), combinations of 2-cyanophenyl and 4-methyl-5-isopropylthiazole moieties, showed extremely potent anti-HIV-1 activity. The EC<sub>50</sub> values of 101 and 18b were 0.0017 and 0.0018 μM, respectively. These values were lower than that of efavirenz (3). Compound 11g (YM-215389), a combination of 2-hydroxyphenyl and 4-chloro-5-isopropylthiazole moieties, proved to be the most active against both K103N and Y181C RTs with IC<sub>50</sub> values of 0.043 and 0.013 μM, respectively.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0968-0896</s0></fA01><fA03 i2="1"><s0>Bioorg. med. chem.</s0></fA03><fA05><s2>13</s2></fA05><fA06><s2>4</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives</s1></fA08><fA11 i1="01" i2="1"><s1>MASUDA (Naoyuki)</s1></fA11><fA11 i1="02" i2="1"><s1>YAMAMOTO (Osamu)</s1></fA11><fA11 i1="03" i2="1"><s1>FUJII (Masahiro)</s1></fA11><fA11 i1="04" i2="1"><s1>OHGAMI (Tetsuro)</s1></fA11><fA11 i1="05" i2="1"><s1>FUJIYASU (Jiro)</s1></fA11><fA11 i1="06" i2="1"><s1>KONTANI (Toru)</s1></fA11><fA11 i1="07" i2="1"><s1>MORITOMO (Ayako)</s1></fA11><fA11 i1="08" i2="1"><s1>ORITA (Masaya)</s1></fA11><fA11 i1="09" i2="1"><s1>KURIHARA (Hiroyuki)</s1></fA11><fA11 i1="10" i2="1"><s1>KOGA (Hironobu)</s1></fA11><fA11 i1="11" i2="1"><s1>KAGEYAMA (Shunji)</s1></fA11><fA11 i1="12" i2="1"><s1>OHTA (Mitsuaki)</s1></fA11><fA11 i1="13" i2="1"><s1>INOUE (Hiroshi)</s1></fA11><fA11 i1="14" i2="1"><s1>HATTA (Toshifumi)</s1></fA11><fA11 i1="15" i2="1"><s1>SHINTANI (Masafumi)</s1></fA11><fA11 i1="16" i2="1"><s1>SUZUKI (Hiroshi)</s1></fA11><fA11 i1="17" i2="1"><s1>SUDO (Kenji)</s1></fA11><fA11 i1="18" i2="1"><s1>SHIMIZU (Yasuaki)</s1></fA11><fA11 i1="19" i2="1"><s1>KODAMA (Eiichi)</s1></fA11><fA11 i1="20" i2="1"><s1>MATSUOKA (Masao)</s1></fA11><fA11 i1="21" i2="1"><s1>FUJIWARA (Masatoshi)</s1></fA11><fA11 i1="22" i2="1"><s1>YOKOTA (Tomoyuki)</s1></fA11><fA11 i1="23" i2="1"><s1>SHIGETA (Shiro)</s1></fA11><fA11 i1="24" i2="1"><s1>BABA (Masanori)</s1></fA11><fA14 i1="01"><s1>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka</s1><s2>Tsukuba, Ibaraki 305-8585</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ></fA14><fA14 i1="02"><s1>Laboratory of Virus Immunology, Institute for Virus Research, Kyoto University, 53 Syogoin, Kawaramachi</s1><s2>Sakyo-ku, Kyoto 606-8507</s2><s3>JPN</s3><sZ>19 aut.</sZ><sZ>20 aut.</sZ></fA14><fA14 i1="03"><s1>Rational Drug Design Laboratories, 4-1-1, Misato</s1><s2>Matsukawa-Machi, Fukushima 960-1242</s2><s3>JPN</s3><sZ>21 aut.</sZ><sZ>22 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Microbiology, School of Medicine, Fukushima Medical University</s1><s2>I Hikarigaoka, Fukushima 960-1295</s2><s3>JPN</s3><sZ>23 aut.</sZ></fA14><fA14 i1="05"><s1>Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University</s1><s2>8-35-1 Sakuragaoka, Kagoshima 890-8544</s2><s3>JPN</s3><sZ>24 aut.</sZ></fA14><fA20><s1>949-961</s1></fA20><fA21><s1>2005</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>26564</s2><s5>354000125945790020</s5></fA43><fA44><s0>0000</s0><s1>© 2005 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>15 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>05-0202368</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Bioorganic & medicinal chemistry</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>In a previous study, we described the structure-activity relationships (SARs) for a series of thiazolidenebenzenesulfonamide derivatives. These compounds were found to be highly potent inhibitors of the wild type (WT) and Y181C mutant reverse transcriptases (RTs) and modest inhibitors of K103N RT. These molecules are thus considered to be a novel class of non-nucleoside HIV-1 RT inhibitors (NNRTIs). In this paper, we have examined the effects of substituents on both the thiazolidene and benzenesulfonamide moieties. Introduction of a 2-cyanophenyl ring into these moieties significantly enhanced anti-HIV-1 activity, whereas a 2-hydroxyphenyl group endowed potent activity against RTs, including K103N and Y181C mutants. Among the series of molecules examined, 101 and 18b (YM-228855), combinations of 2-cyanophenyl and 4-methyl-5-isopropylthiazole moieties, showed extremely potent anti-HIV-1 activity. The EC<sub>50</sub> values of 101 and 18b were 0.0017 and 0.0018 μM, respectively. These values were lower than that of efavirenz (3). Compound 11g (YM-215389), a combination of 2-hydroxyphenyl and 4-chloro-5-isopropylthiazole moieties, proved to be the most active against both K103N and Y181C RTs with IC<sub>50</sub> values of 0.043 and 0.013 μM, respectively.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02S05</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Relation structure activité</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Structure activity relation</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Relación estructura actividad</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Synthèse chimique</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Chemical synthesis</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Síntesis química</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Sulfonamide</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Sulfonamide</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Sulfonamida</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Thiazole dérivé</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Thiazole derivatives</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Tiazol derivado</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Nitrile</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Nitrile</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Nitrilo</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Benzène dérivé</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Benzene derivatives</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Benceno derivado</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Hétérocycle soufre azote</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Sulfur nitrogen heterocycle</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Heterociclo azufre nitrógeno</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Composé non nucléoside</s0><s5>10</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Non nucleoside compound</s0><s5>10</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Compuesto no nucleósido</s0><s5>10</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0><s5>16</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Enzyme inhibitor</s0><s5>16</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Inhibidor enzima</s0><s5>16</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Inhibiteur reverse transcriptase</s0><s2>NK</s2><s2>FR</s2><s5>17</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Reverse transcriptase inhibitor</s0><s2>NK</s2><s2>FR</s2><s5>17</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Inhibitor reverse transcriptase</s0><s2>NK</s2><s2>FR</s2><s5>17</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>RNA-directed DNA polymerase</s0><s2>FE</s2><s5>18</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>RNA-directed DNA polymerase</s0><s2>FE</s2><s5>18</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>RNA-directed DNA polymerase</s0><s2>FE</s2><s5>18</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Antiviral</s0><s5>19</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Antiviral</s0><s5>19</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Antiviral</s0><s5>19</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Virus HIV1</s0><s2>NW</s2><s5>20</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>HIV-1 virus</s0><s2>NW</s2><s5>20</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>HIV-1 virus</s0><s2>NW</s2><s5>20</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>In vitro</s0><s5>21</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>In vitro</s0><s5>21</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>In vitro</s0><s5>21</s5></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Anti hiv</s0><s4>INC</s4><s5>77</s5></fC03><fC03 i1="16" i2="X" l="FRE"><s0>Benzènesulfonamide(5-chloro-2-cyano-N-[3,4-diméthyl-5-isopropylthiazolin-2-ylidène])</s0><s2>FR</s2><s2>NK</s2><s4>INC</s4><s5>78</s5></fC03><fC03 i1="17" i2="X" l="FRE"><s0>Benzènesulfonamide(5-bromo-N-[4-chloro-5-isopropyl-3-méthylthiazolin-2-ylidène]-2-hydroxy)</s0><s2>FR</s2><s2>NK</s2><s4>INC</s4><s5>79</s5></fC03><fC03 i1="18" i2="X" l="FRE"><s0>Benzène-1,4-dicarbonitrile dérivé</s0><s2>NK</s2><s4>INC</s4><s5>80</s5></fC03><fC03 i1="19" i2="X" l="FRE"><s0>Benzènesulfonamide(2,5-dicyano-N-[3,4-diméthyl-5-isopropylthiazolin-2-ylidène])</s0><s2>FR</s2><s2>NK</s2><s4>INC</s4><s5>81</s5></fC03><fC03 i1="20" i2="X" l="FRE"><s0>YM 215389</s0><s2>FR</s2><s4>INC</s4><s5>82</s5></fC03><fC03 i1="21" i2="X" l="FRE"><s0>YM 228855</s0><s2>FR</s2><s4>INC</s4><s5>83</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Chlore Composé organique</s0><s2>NC</s2><s2>FX</s2><s2>NA</s2><s5>07</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Chlorine Organic compounds</s0><s2>NC</s2><s2>FX</s2><s2>NA</s2><s5>07</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Cloro Compuesto orgánico</s0><s2>NC</s2><s2>FX</s2><s2>NA</s2><s5>07</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Brome Composé organique</s0><s2>NC</s2><s2>FR</s2><s2>FX</s2><s2>NA</s2><s5>08</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Bromine Organic compounds</s0><s2>NC</s2><s2>FR</s2><s2>FX</s2><s2>NA</s2><s5>08</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Bromo Compuesto orgánico</s0><s2>NC</s2><s2>FR</s2><s2>FX</s2><s2>NA</s2><s5>08</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Nucleotidyltransferases</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Nucleotidyltransferases</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Nucleotidyltransferases</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Transferases</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Transferases</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Transferases</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Virus immunodéficience humaine</s0><s2>NW</s2></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Human immunodeficiency virus</s0><s2>NW</s2></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Human immunodeficiency virus</s0><s2>NW</s2></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Lentivirus</s0><s2>NW</s2></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Lentivirus</s0><s2>NW</s2></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Lentivirus</s0><s2>NW</s2></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fN21><s1>143</s1></fN21><fN44 i1="01"><s1>PSI</s1></fN44><fN82><s1>PSI</s1></fN82></pA></standard><server><NO>PASCAL 05-0202368 INIST</NO><ET>Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives</ET><AU>MASUDA (Naoyuki); YAMAMOTO (Osamu); FUJII (Masahiro); OHGAMI (Tetsuro); FUJIYASU (Jiro); KONTANI (Toru); MORITOMO (Ayako); ORITA (Masaya); KURIHARA (Hiroyuki); KOGA (Hironobu); KAGEYAMA (Shunji); OHTA (Mitsuaki); INOUE (Hiroshi); HATTA (Toshifumi); SHINTANI (Masafumi); SUZUKI (Hiroshi); SUDO (Kenji); SHIMIZU (Yasuaki); KODAMA (Eiichi); MATSUOKA (Masao); FUJIWARA (Masatoshi); YOKOTA (Tomoyuki); SHIGETA (Shiro); BABA (Masanori)</AU><AF>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka/Tsukuba, Ibaraki 305-8585/Japon (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut., 9 aut., 10 aut., 11 aut., 12 aut., 13 aut., 14 aut., 15 aut., 16 aut., 17 aut., 18 aut.); Laboratory of Virus Immunology, Institute for Virus Research, Kyoto University, 53 Syogoin, Kawaramachi/Sakyo-ku, Kyoto 606-8507/Japon (19 aut., 20 aut.); Rational Drug Design Laboratories, 4-1-1, Misato/Matsukawa-Machi, Fukushima 960-1242/Japon (21 aut., 22 aut.); Department of Microbiology, School of Medicine, Fukushima Medical University/I Hikarigaoka, Fukushima 960-1295/Japon (23 aut.); Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University/8-35-1 Sakuragaoka, Kagoshima 890-8544/Japon (24 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Bioorganic & medicinal chemistry; ISSN 0968-0896; Royaume-Uni; Da. 2005; Vol. 13; No. 4; Pp. 949-961; Bibl. 15 ref.</SO><LA>Anglais</LA><EA>In a previous study, we described the structure-activity relationships (SARs) for a series of thiazolidenebenzenesulfonamide derivatives. These compounds were found to be highly potent inhibitors of the wild type (WT) and Y181C mutant reverse transcriptases (RTs) and modest inhibitors of K103N RT. These molecules are thus considered to be a novel class of non-nucleoside HIV-1 RT inhibitors (NNRTIs). In this paper, we have examined the effects of substituents on both the thiazolidene and benzenesulfonamide moieties. Introduction of a 2-cyanophenyl ring into these moieties significantly enhanced anti-HIV-1 activity, whereas a 2-hydroxyphenyl group endowed potent activity against RTs, including K103N and Y181C mutants. Among the series of molecules examined, 101 and 18b (YM-228855), combinations of 2-cyanophenyl and 4-methyl-5-isopropylthiazole moieties, showed extremely potent anti-HIV-1 activity. The EC<sub>50</sub> values of 101 and 18b were 0.0017 and 0.0018 μM, respectively. These values were lower than that of efavirenz (3). Compound 11g (YM-215389), a combination of 2-hydroxyphenyl and 4-chloro-5-isopropylthiazole moieties, proved to be the most active against both K103N and Y181C RTs with IC<sub>50</sub> values of 0.043 and 0.013 μM, respectively.</EA><CC>002B02S05</CC><FD>Relation structure activité; Synthèse chimique; Sulfonamide; Thiazole dérivé; Nitrile; Benzène dérivé; Hétérocycle soufre azote; Composé non nucléoside; Inhibiteur enzyme; Inhibiteur reverse transcriptase; RNA-directed DNA polymerase; Antiviral; Virus HIV1; In vitro; Anti hiv; Benzènesulfonamide(5-chloro-2-cyano-N- [3,4-diméthyl-5-isopropylthiazolin-2-ylidène]); Benzènesulfonamide(5-bromo-N-[4-chloro-5-isopropyl-3-méthylthiazolin-2-ylidène]-2-hydroxy); Benzène-1,4-dicarbonitrile dérivé; Benzènesulfonamide(2,5-dicyano-N-[3,4-diméthyl-5-iso propylthiazolin-2-ylidène]); YM 215389; YM 228855</FD><FG>Chlore Composé organique; Brome Composé organique; Nucleotidyltransferases; Transferases; Enzyme; Virus immunodéficience humaine; Lentivirus; Retroviridae; Virus</FG><ED>Structure activity relation; Chemical synthesis; Sulfonamide; Thiazole derivatives; Nitrile; Benzene derivatives; Sulfur nitrogen heterocycle; Non nucleoside compound; Enzyme inhibitor; Reverse transcriptase inhibitor; RNA-directed DNA polymerase; Antiviral; HIV-1 virus; In vitro</ED><EG>Chlorine Organic compounds; Bromine Organic compounds; Nucleotidyltransferases; Transferases; Enzyme; Human immunodeficiency virus; Lentivirus; Retroviridae; Virus</EG><SD>Relación estructura actividad; Síntesis química; Sulfonamida; Tiazol derivado; Nitrilo; Benceno derivado; Heterociclo azufre nitrógeno; Compuesto no nucleósido; Inhibidor enzima; Inhibitor reverse transcriptase; RNA-directed DNA polymerase; Antiviral; HIV-1 virus; In vitro</SD><LO>INIST-26564.354000125945790020</LO><ID>05-0202368</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000701 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000701 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:05-0202368
|texte= Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives
}}
| This area was generated with Dilib version V0.6.33. |  |